Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two major investor conferences in December 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, at 10:00 a.m. ET, and the Citi 2024 Global Healthcare Conference on Wednesday, December 4, at 2:30 p.m. ET. Live webcasts will be available on Travere's investor relations website, with replays accessible for 30 days after each event.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +4.84%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:
7th Annual Evercore HealthCONx Conference
Tuesday, December 3, 2024, at 10:00 a.m. ET
Citi 2024 Global Healthcare Conference
Wednesday, December 4, 2024, at 2:30 p.m. ET
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact:
| Investors: 888-969-7879 IR@travere.com | Media: 888-969-7879 mediarelations@travere.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.